Niagen Bioscience Inc

Total Valuation

Niagen Bioscience Inc carries a market capitalization of 273.98M, placing it among publicly traded companies globally. Its enterprise value stands at 286.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Niagen Bioscience Inc currently has 79.46M shares outstanding.

Valuation Ratios

Niagen Bioscience Inc trades at a trailing price-to-earnings ratio of 18.81. The price-to-sales ratio is 2.69, and the price-to-book ratio stands at -2.22.

Enterprise Valuation

On an enterprise value basis, Niagen Bioscience Inc trades at an EV/EBITDA multiple of 22.67 and an EV/FCF ratio of 60.38. The EV/Sales ratio of 2.20 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.83 provides insight into valuation relative to core operating earnings.

Financial Position

Niagen Bioscience Inc maintains a current ratio of 4.61, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Niagen Bioscience Inc has paid 1.06M in income taxes, reflecting an effective tax rate of 5.38.

Stock Price Statistics

Niagen Bioscience Inc's stock has declined approximately -70.79796% over the past 52 weeks. The 50-day moving average sits at 4.36, while the 200-day moving average is 6.37.

Income Statement

Over the trailing twelve months, Niagen Bioscience Inc generated 130.42M in revenue and converted that into 18.64M in net income, yielding earnings per share of 0.22. EBITDA reached 12.65M, while operating income came in at 11.10M.

Balance Sheet

Niagen Bioscience Inc holds 66.40M in cash and equivalents against 2.58M in total debt, resulting in a net debt position of -66.40M. Total book value stands at -158.13M, with working capital of 82.30M providing operational flexibility.

Cash Flow

Niagen Bioscience Inc produced 4.43M in operating cash flow over the past twelve months. After subtracting -321,000.00 in capital expenditures, free cash flow totaled 4.11M - equivalent to 0.05 per share.

Margins

Niagen Bioscience Inc operates with a gross margin of 64.28, reflecting its pricing power and cost economics. The operating margin of 8.51 and net profit margin of 14.29 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Niagen Bioscience Inc's most recent stock split took place on April 13, 2016 with a 3:1 split ratio.

Scores

Niagen Bioscience Inc posts an Altman Z-Score of 6.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.